Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options.
• Epidermal growth factor receptor (EGFR) is often overexpressed in TNBC, driving tumor growth and metastasis.
• Current single-agent EGFR inhibition shows restricted clinical benefit.

Purpose of the Study:

• To review the role of EGFR in TNBC.
• To explore genomic and non-genomic determinants of EGFR expression.
• To evaluate combinatorial and multi-targeted therapy approaches for TNBC.

Main Methods:

• Analysis of gene expression patterns in EGFR-high and EGFR-low TNBC samples.
• Identification of co-targeting factors to enhance anti-EGFR efficacy.
• Review of nanocarrier systems for dual-agent delivery.

Main Results:

• EGFR expression varies across TNBC subtypes.
• Co-targeting factors were identified to improve anti-EGFR therapy efficacy.
• Simultaneous targeting impacts patient survival outcomes.
• Nanocarriers can deliver multiple therapeutic agents for EGFR and co-expressed targets.

Conclusions:

• Combinatorial and multi-targeted therapies hold significant potential for improving TNBC treatment.
• Identifying co-targeting factors enables more precise and personalized treatment strategies.
• Nanotechnology offers promising delivery systems for enhanced TNBC therapy.